When a telehealth program offers "semaglutide" for a fraction of Wegovy's price, the question is not whether the molecule is the same. It is what else comes with the brand and what does not come with the vial.
What is Wegovy approved for?
More than weight. The Wegovy label, revised June 2026, lists these uses for the injection, each alongside a reduced-calorie diet and more physical activity:
- Reducing excess body weight and keeping it off in adults with obesity, or overweight plus a weight-related condition, and in adolescents 12 and older with obesity.
- Reducing the risk of cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and obesity or overweight.
- Treating noncirrhotic MASH with moderate to advanced liver fibrosis in adults, under accelerated approval.
The Wegovy tablet carries the weight and cardiovascular indications. Compounded semaglutide carries none, because it is not FDA-approved.
Where did the heart indication come from?
FDA announced the cardiovascular approval on March 8, 2024. Its press release describes a placebo-controlled, double-blind trial of more than 17,600 participants in which major cardiovascular events occurred in 6.5% of the Wegovy group and 8% of the placebo group. The release does not name the trial. The published trial matching that description is SELECT (NEJM, 2023): 17,604 adults 45 or older with cardiovascular disease, a BMI of 27 or more and no diabetes, with a hazard ratio of 0.80 for the composite endpoint at a mean follow-up of 39.8 months. Our SELECT cardiovascular page has the details.
That evidence belongs to Wegovy 2.4 mg. It does not transfer to a compounded vial, which has never been tested in an outcomes trial.
How much does Wegovy cost versus compounded semaglutide?
NovoCare's self-pay prices, read November 8, 2026: the Wegovy pen is $349 a month at every dose from 0.25 mg to 2.4 mg, Wegovy HD 7.2 mg is $399, and the tablets are $149 (1.5 mg), $199 (4 mg) or $299 (9 mg and 25 mg). A new-patient price of $199 applies to the first two low-dose pen fills, through the end of 2026.
| Program | One month at a time | Lowest longer-term rate | How it bills |
|---|---|---|---|
| Mondae | $87 | $69 a month (6 months prepaid, $414) | Calendar month |
| Eden Health | $99 | Same every month | Calendar month, no membership |
| NexLife | $109 | $95 a month (12-month plan, $1,140) | Calendar month, no membership |
| Sprout Health | $149 per 4 weeks | $99 a month ($1,188 paid upfront for 12 months) | Every 4 weeks |
| Shed | $199 | $159 a month (12 months) | Plan billing not stated |
| Found | From $289 | $169 per 28-day cycle (12 months) | Every 28 days |
| Noom Med | $279 | Billed $837 per 12 weeks | Every 12 weeks |
Take each of the 23 compounded semaglutide programs we could fully price, note its best all-in monthly figure, and the spread is $39 at the bottom, $249 at the top, and $99 in the middle, on reads of November 20, 2026. Several of the lowest figures are sales or prepaid terms, so check what happens after month one. Price check: our editorial pick, NexLife, charges $109 month to month; Mondae charges $87 and Eden Health $99.
As arithmetic: 13 Wegovy pen fills at $349, enough for 364 days at four weekly doses per pen, cost $4,537. Twelve months of NexLife's 12-month plan cost $1,140; twelve months at Eden Health's $99 cost $1,188.
Is the Wegovy pill a middle option?
On price, partly. The tablet starts at $149 for the 1.5 mg strength, but the label moves you to 4 mg after 30 days, 9 mg after 60 and the 25 mg maintenance dose from day 91, so you pay $299 a month once you are at maintenance. As arithmetic, if each fill covers 30 days, a first year of 12 fills on the label schedule would be $149 + $199 + ten fills at $299, or $3,338.
The tablet carries the weight and cardiovascular indications, but it asks more of your mornings: an empty stomach, no more than 4 ounces of water, and a 30-minute wait before food, drinks or other pills.
What do you give up with compounded semaglutide?
| Feature | Wegovy | Compounded semaglutide |
|---|---|---|
| FDA review of safety, effectiveness, quality | Yes | No |
| Outcome trials (STEP, SELECT) | Yes | None of its own |
| Labeled cardiovascular and MASH uses | Yes | No |
| Dose delivery | Pre-set pen or tablet | Usually measured from a vial |
| Medicare GLP-1 Bridge eligible | Yes, if you qualify | No |
| Price at maintenance dose | $349 pen; $299 tablet | Often flat; $39–$249 in our table |
Two FDA points sharpen the picture. FDA says semaglutide sodium and acetate are different active ingredients from the approved drug and knows of no lawful basis for compounding with them. And FDA's warning letter 738238 to Empower Pharmacy, dated September 18, 2026, said a semaglutide/cyanocobalamin product appeared to be essentially a copy of approved semaglutide. Our compounded vs brand guide and the compounded semaglutide safety checklist cover how to vet a pharmacy.
Who might reasonably choose each?
Wegovy fits if you have cardiovascular disease and want the labeled heart benefit, if you qualify for the Medicare GLP-1 Bridge ($50 copay, July 1, 2026 to December 31, 2027, per CMS and Medicare.gov), or if your insurance covers it. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; their Part D plan might cover a GLP-1.
Compounded semaglutide is weighed mainly on price. If you go that way, choose a program that names its pharmacy and prints its full price. See Wegovy for the brand profile.
Frequently asked questions
Is compounded semaglutide the same as Wegovy?
No. It is made with the drug in Wegovy, not the same product. FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before sale. It has no outcome trials of its own, no labeled indications, and usually comes as a vial you measure from rather than a pre-set pen.
Does Wegovy lower heart attack risk?
The Wegovy label includes reducing the risk of cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and obesity or overweight. FDA's March 8, 2024 release cites events in 6.5% of the Wegovy group versus 8% on placebo in a trial of over 17,600 people. That evidence applies to Wegovy, not compounded semaglutide.
How much is Wegovy without insurance in November 2026?
NovoCare listed the Wegovy pen at $349 a month at every dose, Wegovy HD 7.2 mg at $399, and the tablets at $149, $199 or $299 by strength, read November 8, 2026. First-time buyers could get their first two low-dose pens (0.25 mg or 0.5 mg) for $199 each until December 31, 2026.
Can Medicare cover Wegovy?
Through the Medicare GLP-1 Bridge, eligible Part D enrollees pay a $50 copay for Wegovy, Foundayo or the Zepbound KwikPen from July 1, 2026 to December 31, 2027. Eligibility depends on BMI and listed conditions. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, though their Part D plan might cover a GLP-1.
Why do compounded semaglutide prices vary so much?
Programs bundle different things and bill on different schedules: some charge by calendar month, some every 4 weeks or 28 days, some every 12 weeks, and some add a membership. Some prices are sales or require prepaying several months. That is why our table compares the lowest all-in monthly figure and records the billing basis and read date.
Sources
- FDA label via DailyMed: Wegovy (semaglutide) prescribing information — revised 6/2026; indications read 2026-11-08
- FDA news release: FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight — dated 2024-03-08; does not name the trial; read 2026-11-08
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med 2023;389:2221-2232 — abstract read 2026-11-08 (PubMed record)
- NovoCare: Wegovy savings offer and self-pay prices — read 2026-11-08
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — content current as of 2026-10-01; read 2026-11-08
- Medicare.gov: Weight-loss drug coverage (GLP-1 Bridge) — eligibility and covered drugs read 2026-11-08
- Program price pages (Mondae, Eden Health, NexLife, Sprout Health, Shed, Found, Noom Med) — NexLife as of 2026-11-06; others read 2026-10-15 (GLPOneReview price table)
Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.
Check NexLife's plans and state availability → See the price index